REPL vs UTHR · $825.7M cap vs P/E 20, rev $2.88B
Replimune Group Inc (REPL) versus United Therapeutics Corporation (UTHR) — a side-by-side from cached financials, not a winner call.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
United Therapeutics Corporation (UTHR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
REPL does not have a complete income-statement cache yet.
Latest reported UTHR revenue for 2024-12-31 was $2.88B. Net income was $1.20B. Revenue was up 23.6% from 2023-12-31 to 2024-12-31. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
REPL currently screens at market cap $825.7M. UTHR currently screens at market cap $23.41B and trailing P/E 20.4.
Not investment advice. Open the REPL and UTHR stock pages for the full models.
Not investment advice.